FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012184265> ?p ?o ?g. }

• W2012184265 endingPage "998" @default.
• W2012184265 startingPage "992" @default.
• W2012184265 abstract "No AccessJournal of UrologyAdult Urology1 Sep 2013Familiarity and Self-Reported Compliance with American Urological Association Best Practice Recommendations for Use of Thromboembolic Prophylaxis among American Urological Association Members Steve Sterious, Jay Simhan, Robert G. Uzzo, Boris Gershman, Tianyu Li, Karthik Devarajan, Daniel Canter, John Walton, Ryan Fogg, Serge Ginzburg, Anthony Corcoran, Marc C. Smaldone, and Alexander Kutikov Steve SteriousSteve Sterious Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Equal study contribution. Nothing to disclose. More articles by this author , Jay SimhanJay Simhan Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Equal study contribution. Nothing to disclose. More articles by this author , Robert G. UzzoRobert G. Uzzo Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Financial interest and/or other relationship with Pfizer and Wilex. More articles by this author , Boris GershmanBoris Gershman Department of Urology, Massachusetts General Hospital, Boston, Massachusetts Nothing to disclose. More articles by this author , Tianyu LiTianyu Li Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author , Karthik DevarajanKarthik Devarajan Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author , Daniel CanterDaniel Canter Department of Urology, Emory School of Medicine, Winship Cancer Institute, Atlanta, Georgia Nothing to disclose. More articles by this author , John WaltonJohn Walton Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author , Ryan FoggRyan Fogg Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author , Serge GinzburgSerge Ginzburg Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author , Anthony CorcoranAnthony Corcoran Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author , Marc C. SmaldoneMarc C. Smaldone Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author , and Alexander KutikovAlexander Kutikov Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Financial interest and/or other relationship with UrologyMatch.com and Visible Health Inc. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.03.076AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Thromboprophylaxis with subcutaneous heparin or low molecular weight heparin is now an integral part of national surgical quality and safety assessment efforts, and has been incorporated into the current AUA Best Practice Statement. We evaluated familiarity and compliance with the AUA Best Practice Statement, assessed practice patterns in terms of perioperative thromboprophylaxis and specifically examined self-reported compliance in high risk patients undergoing radical cystectomy. Materials and Methods: An electronic survey was sent to AUA members with valid e-mail addresses (10,966). Associations between AUA Best Practice Statement adherence and factors such as urological specialty, graduation year and guideline familiarity were assessed using chi-square analyses and generalized estimating equations. Results: With 1,210 survey responses the largest group of respondents was urological oncologists and/or laparoscopic/robotic specialists (26.0%). This group was more likely to use thromboprophylaxis than nonurological oncologists and/or laparoscopic/robotic specialists in high risk patients (OR 1.3, CI 1.1–1.5). Respondents aware of the AUA Best Practice Statement guidelines (50.7%) were more likely to use thromboprophylaxis (OR 1.4, CI 1.2–1.6). Although 18.1% of urological oncologists and/or laparoscopic/robotic specialists and 34.2% of nonurological oncologists and/or laparoscopic/robotic specialists avoided routine thromboprophylaxis in patients undergoing radical cystectomy, the former were more likely to use thromboprophylaxis (p <0.0001) than other respondents. Urologists graduating after the year 2000 used thromboprophylaxis in high risk patients undergoing radical cystectomy more often than did earlier graduates (79.2% vs 63.4%, p <0.0001). Conclusions: Although younger age and self-reported urological oncologist and/or laparoscopic/robotic specialist status correlated strongly with thromboprophylaxis use, self-reported adherence to AUA Best Practice Statement was low, even in high risk cases with clear AUA Best Practice Statement recommendations such as radical cystectomy. These data identify opportunities for quality improvement in patients undergoing major urological surgery. References 1 : American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol2007; 25: 5490. Google Scholar 2 : Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery. J Urol1995; 153: 1763. Link, Google Scholar 3 : Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin.Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med1988; 318: 1162. Google Scholar 4 : Venous Thromboembolism. www.jointcommission.org/venous_thromboembolism. Accessed December 13, 2012. Google Scholar 5 : AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol2009; 181: 1170. Link, Google Scholar 6 : Models for longitudinal data: a generalized estimating equation approach. Biometrics1988; 44: 1049. Google Scholar 7 : Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. In: . : 2009: 29. Google Scholar 8 : Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008; 133: 381S. Google Scholar 9 : A critical analysis of perioperative mortality from radical cystectomy. J Urol2006; 175: 886. Link, Google Scholar 10 : Low molecular weight heparin and radical prostatectomy: a prospective analysis of safety and side effects. Prostate Cancer Prostatic Dis1997; 1: 101. Google Scholar 11 : Venous thrombosis prophylaxis for urological laparoscopy: fractionated heparin versus sequential compression devices. J Urol2005; 173: 1623. Link, Google Scholar 12 : American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am2012; 94: 746. Google Scholar 13 : Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery. Surg Endosc2007; 21: 1007. Google Scholar 14 : Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur J Anaesthesiol2006; 23: 95. Google Scholar 15 : Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol2007; 51: 130. Google Scholar 16 : Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted?. BJU Int2005; 96: 1019. Google Scholar 17 : Heparin prophylaxis and the risk of venous thromboembolism after robotic-assisted laparoscopic prostatectomy. BJU Int2011; 108: 729. Google Scholar 18 : Risk of deep venous thrombosis and pulmonary embolism in urogynecologic surgical patients. Am J Obstet Gynecol2010; 203: 510. Google Scholar 19 : Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol2008; 53: 134. Google Scholar 20 : Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology2006; 68: 988. Google Scholar 21 : Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol2012; 30: 4416. Google Scholar 22 : Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003; 349: 859. Google Scholar 23 : Prospective analysis of pulmonary embolism in the postoperative patient. Surgery1970; 68: 116. Google Scholar 24 : Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg1988; 208: 227. Google Scholar 25 : Thromboprophylaxis for radical prostatectomy: a comparative analysis of present practice between the USA, the UK, and Ireland. Prostate2004; 60: 338. Google Scholar 26 : Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol2011; 185: 407. Link, Google Scholar 27 : Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. BJU Int2012; 110: 967. Google Scholar 28 : Thou shalt versus thou shalt not: a meta-synthesis of GPs' attitudes to clinical practice guidelines. Br J Gen Pract2007; 57: 971. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byKlaassen Z, Arora K, Goldberg H, Chandrasekar T, Wallis C, Sayyid R, Fleshner N, Finelli A, Kutikov A, Violette P and Kulkarni G (2018) Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current GuidelinesJournal of Urology, VOL. 199, NO. 4, (906-914), Online publication date: 1-Apr-2018.Joshi S and Chen D (2018) Editorial CommentJournal of Urology, VOL. 197, NO. 2, (307-307), Online publication date: 1-Feb-2017.Griebling T (2018) Re: Association between Testosterone Supplementation Therapy and Thrombotic Events in Elderly MenJournal of Urology, VOL. 196, NO. 2, (519-520), Online publication date: 1-Aug-2016.Duivenvoorden W, Daneshmand S, Canter D, Lotan Y, Black P, Abdi H, van Rhijn B, Fransen van de Putte E, Zareba P, Koskinen I, Kassouf W, Traboulsi S, Kukreja J, Boström P, Shayegan B and Pinthus J (2018) Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant ChemotherapyJournal of Urology, VOL. 196, NO. 6, (1627-1633), Online publication date: 1-Dec-2016.Kabarriti A, Pietzak E, Drach G and Guzzo T (2018) Surgical Considerations for the Geriatric Urology PatientUrology Practice, VOL. 3, NO. 2, (153-163), Online publication date: 1-Mar-2016.Otto B, Osterberg E, Salgado S, Scherr D and Shariat S (2018) Prostate Cancer Risk Estimation Tool Use by Members of the American Urological Association: A Survey Based StudyJournal of Urology, VOL. 193, NO. 6, (1933-1937), Online publication date: 1-Jun-2015.Steers W (2018) This Month in Adult UrologyJournal of Urology, VOL. 190, NO. 3, (825-826), Online publication date: 1-Sep-2013. Volume 190Issue 3September 2013Page: 992-998Supplementary Materials Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordsprevention and controlsocieties, medicalthromboembolismheparinpractice guidelines as topicAcknowledgmentsThe American Urological Association provided access to their member registry.MetricsAuthor Information Steve Sterious Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Equal study contribution. Nothing to disclose. More articles by this author Jay Simhan Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Equal study contribution. Nothing to disclose. More articles by this author Robert G. Uzzo Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Financial interest and/or other relationship with Pfizer and Wilex. More articles by this author Boris Gershman Department of Urology, Massachusetts General Hospital, Boston, Massachusetts Nothing to disclose. More articles by this author Tianyu Li Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author Karthik Devarajan Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author Daniel Canter Department of Urology, Emory School of Medicine, Winship Cancer Institute, Atlanta, Georgia Nothing to disclose. More articles by this author John Walton Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author Ryan Fogg Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author Serge Ginzburg Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author Anthony Corcoran Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author Marc C. Smaldone Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Nothing to disclose. More articles by this author Alexander Kutikov Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, Pennsylvania Financial interest and/or other relationship with UrologyMatch.com and Visible Health Inc. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2012184265 created "2016-06-24" @default.
• W2012184265 creator A5006253852 @default.
• W2012184265 creator A5008758912 @default.
• W2012184265 creator A5023838103 @default.
• W2012184265 creator A5031081545 @default.
• W2012184265 creator A5033357081 @default.
• W2012184265 creator A5034117842 @default.
• W2012184265 creator A5038032242 @default.
• W2012184265 creator A5038940108 @default.
• W2012184265 creator A5043554307 @default.
• W2012184265 creator A5068362325 @default.
• W2012184265 creator A5080057051 @default.
• W2012184265 creator A5084822879 @default.
• W2012184265 creator A5091629756 @default.
• W2012184265 date "2013-09-01" @default.
• W2012184265 modified "2023-09-27" @default.
• W2012184265 title "Familiarity and Self-Reported Compliance with American Urological Association Best Practice Recommendations for Use of Thromboembolic Prophylaxis among American Urological Association Members" @default.
• W2012184265 cites W1549788756 @default.
• W2012184265 cites W1963549371 @default.
• W2012184265 cites W1964677091 @default.
• W2012184265 cites W1971734839 @default.
• W2012184265 cites W1975918912 @default.
• W2012184265 cites W1976566530 @default.
• W2012184265 cites W1979476705 @default.
• W2012184265 cites W1995944914 @default.
• W2012184265 cites W2004569154 @default.
• W2012184265 cites W2016444631 @default.
• W2012184265 cites W2022932023 @default.
• W2012184265 cites W2030697877 @default.
• W2012184265 cites W2042782868 @default.
• W2012184265 cites W2045264175 @default.
• W2012184265 cites W2072341098 @default.
• W2012184265 cites W2080710783 @default.
• W2012184265 cites W2081488805 @default.
• W2012184265 cites W2097323643 @default.
• W2012184265 cites W2102967512 @default.
• W2012184265 cites W2109113725 @default.
• W2012184265 cites W2140718597 @default.
• W2012184265 cites W2148292959 @default.
• W2012184265 cites W4236646914 @default.
• W2012184265 cites W70359381 @default.
• W2012184265 doi "https://doi.org/10.1016/j.juro.2013.03.076" @default.
• W2012184265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23538239" @default.
• W2012184265 hasPublicationYear "2013" @default.
• W2012184265 type Work @default.
• W2012184265 sameAs 2012184265 @default.
• W2012184265 citedByCount "41" @default.
• W2012184265 countsByYear W20121842652013 @default.
• W2012184265 countsByYear W20121842652014 @default.
• W2012184265 countsByYear W20121842652015 @default.
• W2012184265 countsByYear W20121842652016 @default.
• W2012184265 countsByYear W20121842652017 @default.
• W2012184265 countsByYear W20121842652018 @default.
• W2012184265 countsByYear W20121842652019 @default.
• W2012184265 countsByYear W20121842652020 @default.
• W2012184265 countsByYear W20121842652021 @default.
• W2012184265 countsByYear W20121842652022 @default.
• W2012184265 crossrefType "journal-article" @default.
• W2012184265 hasAuthorship W2012184265A5006253852 @default.
• W2012184265 hasAuthorship W2012184265A5008758912 @default.
• W2012184265 hasAuthorship W2012184265A5023838103 @default.
• W2012184265 hasAuthorship W2012184265A5031081545 @default.
• W2012184265 hasAuthorship W2012184265A5033357081 @default.
• W2012184265 hasAuthorship W2012184265A5034117842 @default.
• W2012184265 hasAuthorship W2012184265A5038032242 @default.
• W2012184265 hasAuthorship W2012184265A5038940108 @default.
• W2012184265 hasAuthorship W2012184265A5043554307 @default.
• W2012184265 hasAuthorship W2012184265A5068362325 @default.
• W2012184265 hasAuthorship W2012184265A5080057051 @default.
• W2012184265 hasAuthorship W2012184265A5084822879 @default.
• W2012184265 hasAuthorship W2012184265A5091629756 @default.
• W2012184265 hasConcept C142853389 @default.
• W2012184265 hasConcept C15744967 @default.
• W2012184265 hasConcept C177713679 @default.
• W2012184265 hasConcept C2781460075 @default.
• W2012184265 hasConcept C512399662 @default.
• W2012184265 hasConcept C542102704 @default.
• W2012184265 hasConcept C71924100 @default.
• W2012184265 hasConcept C77805123 @default.
• W2012184265 hasConceptScore W2012184265C142853389 @default.
• W2012184265 hasConceptScore W2012184265C15744967 @default.
• W2012184265 hasConceptScore W2012184265C177713679 @default.
• W2012184265 hasConceptScore W2012184265C2781460075 @default.
• W2012184265 hasConceptScore W2012184265C512399662 @default.
• W2012184265 hasConceptScore W2012184265C542102704 @default.
• W2012184265 hasConceptScore W2012184265C71924100 @default.
• W2012184265 hasConceptScore W2012184265C77805123 @default.
• W2012184265 hasIssue "3" @default.
• W2012184265 hasLocation W20121842651 @default.
• W2012184265 hasLocation W20121842652 @default.
• W2012184265 hasOpenAccess W2012184265 @default.
• W2012184265 hasPrimaryLocation W20121842651 @default.
• W2012184265 hasRelatedWork W1993990554 @default.
• W2012184265 hasRelatedWork W2154214610 @default.
• W2012184265 hasRelatedWork W2358797338 @default.
• W2012184265 hasRelatedWork W2418123316 @default.
• W2012184265 hasRelatedWork W2424059375 @default.

• next